MedPage Today on MSN4h
GLP-1 Drugs and Colonoscopy; GI Symptoms Post-COVID; Identifying High-Risk Barrett'sA systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback